Background: Endovascular aortic repair (EVAR) has emerged as a standard of care for abdominal aortic aneurysm (AAA) repair. However, real-world evidence to compare this technology to open aortic repair (OAR) is limited. Major gaps exist related to long-term outcomes of therapies worldwide.
Treatment of abdominal aortic aneurysms (AAA) has changed remarkably in the last decade. Endovascular aortic repair (EVAR) has become the standard of care for treating intact AAA (iAAA) and is gaining acceptance for treating ruptured AAA (rAAA). Recent analyses of treatment practices in 11 countries participating in the International Consortium of Vascular Registries (ICVR, www.icvr-initiative.org) found that EVAR use is averaging 65% of all iAAA repairs and 30% of all rAAA repairs, demonstrating high use of this minimally invasive treatment. 1 Findings from randomized trials [2] [3] [4] and analyses of administrative data from the United States (U.S.) and United Kingdom (UK) [5] [6] [7] [8] have shown that EVAR is associated with significantly lower perioperative mortality and morbidity compared with open aortic repair (OAR). However, it is unclear whether every patient is eligible for EVAR and what the best practice is for EVAR optimal use because of lack of information on long-term outcomes. Results from the 15-year followup of the UK Endovascular Aneurysm Repair Trial 1 (EVAR Trial 1) have only recently been published. 9 In this randomized trial population, EVAR had early survival benefits but inferior late survival compared with OAR. Randomized controlled trials (RCTs) are known to have limited generalizability, and determining whether these results reflect outcomes in real-world community practice worldwide is important. Data on the use of EVAR and its long-term outcomes in real-world settings is limited. To date, published studies from larger and more generalizable data sources that address both use and long-term outcomes after AAA repair are very limited.
Recent analyses of the Medicare beneficiaries generated valuable long-term results for this large eligible population. 7 However, this database is limited to patients aged $65 years in the U.S. Many patients in the U.S. undergoing AAA repair are younger, and w10% to 15% of all AAA patients in Germany are also aged <65 years. 10 Other large studies using the UK Hospital Episode Statistics or the U.S. Nationwide Inpatient Sample (NIS) are relevant but also have limitations. 8 The NIS, for example, does not permit longitudinal patient linkage and follow-up after hospital discharge. In this context, insurance claims data are emerging as a valuable data source.
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DAK-Gesundheit (DAK-G) is the third largest insurance provider in Germany, and its data have been previously used for studies of infectious diseases, 12 cancer, 13 and severe mental diseases. 14 DAK-G is a powerful data source to study epidemiologic and health service delivery aspects of health care. This study is the first large-scale investigation of AAA outcomes in Germany. We used health insurance claims data to determine the shortand long-term outcomes of EVAR and OAR of iAAA and rAAA and to assess whether recently reported results from RCTs reflect real world practice.
METHODS
The DAK-G health insurance claims data include the outpatient and in-hospital medical care provided to w6.5 million German citizens (8%). In contrast to registry-based data from Germany, 15 For the long-term survival analyses, we censored patients whose insurance contract expired within the follow-up period. A similar percentage of censored cases was present in both groups. The data for this study were categorized into subgroups (intact vs ruptured, OAR vs EVAR), and baseline differences in demographics, comorbidities, and primary and secondary end points were assessed.
The first submitted procedure was considered as the primary case. Two similar procedures submitted on the same day were interpreted as being a double coding error (n ¼ 148). The coding of both EVAR and OAR #3 days of surgery was interpreted as a conversion. Local ethic committee approval was not required for a retrospective analysis of deidentified health insurance claims data, and no patient informed consent was obtained for the study. Multivariable Cox proportional hazard models were conducted to determine the independent effect of EVAR after adjusting for relevant covariates. Selection of the model and range of adjusting covariates were based on the statistical significance of variables in the bivariate model. We then used automated backward selection for the final parsimonious model. Sensitivity analyses using the landmark approach were used to calculate survival, conditional upon surviving the procedure (30 days). Missing values were excluded from the analysis. A P value of < .05 was considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics 23.0 software (IBM, Armonk, NY).
RESULTS
Between October 21, 2008, and April 5, 2015, 8625 patients underwent 14,246 in-hospital treatments for iAAA or rAAA (Fig 1) . AAA repair was performed in 5509 patients, and 3116 patients did not undergo AAA repair. Of these 5509 patients, 4966 were diagnosed with an iAAA and 543 with an rAAA (Fig 1) . A total of 329 patients (6.0%) died during the initial hospital stay (120 after iAAA vs 209 after rAAA), and an additional 930 (16.9%) patients died after being discharged from hospital. EVAR use for iAAA and rAAA repair increased continuously during the study period (2009 to 2014). The proportion of patients operated on with EVAR increased from 59% to 77% (P < .001) for iAAA and from 19% to 37% (P < .005) for rAAA repair. The median follow-up was 2.44 years (range, 0-6.46 years), and loss of follow-up due to leaving the insurer (end of contract) was similar in EVAR and OAR intervention groups for both iAAA and rAAA.
Baseline demographics, comorbidities, and clinical characteristics of DAK-G patients treated with EVAR and OAR are listed in Table I . In iAAA, the most noticeable difference between EVAR and OAR is the significantly higher proportion of patients aged >80 years (octogenarians) receiving EVAR (24.6%) vs OAR (10.6%; P < .001). In rAAA, no statistically significant differences in median age (78 vs 76 years; P ¼ .122) or proportion of octogenarians (45.5% vs 37.6%; P ¼ .104) were seen between EVAR and OAR. Only 55.2% of EVAR patients with an rAAA underwent surgery on the day of admission compared with 78.9% of OAR patients (P < .001).
Outcomes after EVAR vs OAR in iAAA. There were 120 in-hospital deaths (2.4%) after operations for iAAA. In-hospital mortality after EVAR (1.2%) was significantly lower than after OAR (5.4%; P < .001; Table I ). At 30 days after AAA repair, this difference remained significant by Kaplan-Meier estimates of survival (0.984 vs 0.955; P < .001). The in-hospital mortality difference increased with age and was most pronounced in patients aged $80 years, with an in-hospital mortality of 2.2% after EVAR and 18.2% after OAR (P < .001). The median postoperative length of stay was significantly shorter after EVAR than after OAR (6 days [IQR, 5-8 days] vs 11 days [IQR, 9-15 days]; P < .001). Patients who had undergone EVAR had significantly fewer postoperative complications across all measured parameters compared with OAR patients (Table I ). The most noticeable difference between EVAR and OAR was the significantly lower rates of acute bowel ischemia (0.7% vs 2.3%; P < .001), acute renal insufficiency (2.1% vs 11.2%; P < .001), and acute respiratory insufficiency (3.3% vs 13.2%; P < .001) after EVAR.
Kaplan-Meier analyses of survival after iAAA repair are reported in Fig 2, A. Examination of the survival curves show that the early benefit in cumulative survival after elective EVAR is reversed at w1.5 years of follow-up. In the adjusted analyses using Cox proportional hazard models, survival was similar between the EVAR and OAR groups (hazard ratio [HR], 1.028; 95% CI, 0.889-1.188; P ¼ .708; Table II ). Major factors related to survival were hypovolemic shock, acute bowel ischemia, highgrade renal insufficiency, cardiac arrest, history of stroke, and atrial fibrillation or flutter. Gender, diabetes, and history of myocardial infarction were not related to survival.
Outcomes after EVAR vs OAR in rAAA. There were 204 in-hospital deaths in 536 patients (38.1%) undergoing surgery for rAAA (Table I) . In-hospital mortality after EVAR (26.1%) was significantly lower than that after OAR (42.0%; P < .001). At 30 days after AAA repair, this difference remained significant by Kaplan-Meier estimates of survival (0.761 vs 0.614; P < .001). The difference was again most pronounced in patients aged $80 years, with 34.4% in-hospital mortality after EVAR and 62.3% after OAR (P < .001). The median postoperative length of stay was significantly shorter with EVAR than with OAR (10 days [IQR, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] significantly fewer postoperative complications across all measured parameters than OAR patients (Table I) .
Kaplan-Meier analysis of survival after ruptured AAA repair is summarized in Fig 2, B. In the adjusted analyses using the Cox proportional hazard model, survival was not different between the EVAR and OAR groups (HR, 1.150; 95% CI, 0.865-1.528; P ¼ .336; Table III ). The most important predictors in the model were hypovolemic shock (HR, 2.1; 95% CI, 1.7 to 2.7), cardiac arrest (HR, 1.9; 95% CI, 1.3-2.6; P < .001), and acute bowel ischemia (HR, 1.5; 95% CI, 1.1-2.0; P ¼ .019).
Additional analyses of survival conditional upon surviving the procedure. Sensitivity analyses estimated the effect of EVAR on survival beyond discharge (patients who survived at least the first 30 days after procedure).
Risk factors for two cohorts depending on the survival time after AAA repair are listed in Supplementary  Table I (online only) . In these analyses, EVAR was associated with higher mortality for iAAA repair (HR, 1.222; 95% CI, 1.041-1.435; P ¼ .014) and for rAAA repair (HR, 1.866; 95% CI, 1.198-2.907; P ¼ .006; Fig 2, C and D) .
DISCUSSION
In this largest European investigation of AAA outcomes to date using health insurance claims data, we found that elective EVAR is associated with significantly lower in-hospital mortality than OAR (1.2% vs 5.4%) and that this remarkable difference was even stronger in octogenarians (2.2% vs 18.2%; Supplementary Table II, online only). However, we found that EVAR is associated with lower long-term survival for iAAA conditional upon surviving the operation. For rAAA, the in-hospital mortality was again significantly lower after EVAR (26.1% vs 42.0%), with even more difference in octogenarians (34.4% vs 62.3%), and the trends of long-term survival after discharge were similar to those observed for iAAA. In terms of EVAR adoption, we found that EVAR use for iAAA repair is increasing continuously in all age groups in Germany. Overall, we found no statistically significant variation in the annual number of patients being treated for iAAA or rAAA over time. We used complete data from the third largest health insurance company in Germany, which insures w8% of the population. The in-hospital mortality findings of this study are supported by data published from randomized trials 3, 4, 18 and analyses of large administrative data sources in the U.S. and the UK. 5, 7, 8 (Supplementary Table III, online only). However, the trends toward lower cumulative survival after discharge for EVAR are important findings that are novel and are supported by recently published data from 15 years of follow-up of the EVAR Trial 1. 9 Our findings extend the results of the trial that enrolled patients before 2008 and require thorough reflection by the surgical and research communities. To date, there are no other analyses of European administrative data or registries that can confirm or refute our study results from Germany. The findings related to octogenarians with iAAA are of particular importance. Octogenarians benefit tremendously from the use of EVAR technology, with a hospital mortality of just 2.2% compared with 18.2% after OAR (P < .001). No long-term survival concern can negate these important findings. Our findings related to the elderly are supportive of a major investigation by Schermerhorn et al 5 using data from the U.S. Medicare database. In this U.S. study, patients aged >85 years exhibited a 30-day mortality of 2.7% after EVAR vs 11.2% after elective OAR of AAA. 5 Regarding younger and low-risk groups, Siracuse et al 19 analysed the National Surgical Quality Improvement Projects database and reported that early benefits of EVAR persist even in the groups at lowest risk. Although we could not stratify by risk, we found that in-hospital mortality in patients aged <65 years, at 0.2% with EVAR vs 2.3% with OAR (P < .006), also favours EVAR. However, lower long-term survival findings after EVAR are particularly concerning in this age group. For rAAA, a U.S. study using the National Inpatient Sample 20 reported a hospital mortality rate of 41% after OAR and 27% after EVAR. This is very similar to our findings and validates our results. In another study of rAAA, Edwards et al 21 propensity score-matched OAR and EVAR using U.S. Medicare data from 2001 to 2008. The perioperative mortality rate was 33.8% for patients with EVAR vs 47.7% for patients with OAR (P < .001). They also observed a significantly shorter length of stay after EVAR, which is supportive of our findings. A recent prospective analysis of 205 patients by Ambler et al 22 investigated the occurrence of acute kidney injury after rAAA repair. The authors reported that acute kidney injury was common after rAAA repair and that OAR was associated with a higher incidence of severe acute kidney injury (EVAR, 26%; OAR, 43%). In addition, 36% of patients after open rAAA repair needed renal replacement therapy (vs 23% after EVAR). The midterm survival after acute kidney injury after rAAA repair was significantly worse than without this kind of complication. 22 Our study found EVAR was associated with statistically significant lower rates of acute renal insufficiency for both iAAA (2.1% vs 11.2%, P < .001) and rAAA (17.2% vs 38.3%, P < .001) repair, supporting these results. Still, EVAR evidence for rAAA is controversial in light of a Cochrane Review 23 that found no significant difference in the 30-day mortality between open and endovascular approaches in three trials. The conflicting evidence highlights the need for continuous multinational investigations of EVAR for rAAA. Combining data from different national registries requires overcoming barriers such as different policies on data protection and ensuring internal and external validity of data sources. Nevertheless, first approaches have been introduced by the recently founded ICVR. This study has some limitations. Health insurance claims data are not collected for scientific evaluation but rather for reimbursement purposes. Although coding errors are possible, we believe that these errors would affect both operative approaches equally because data collection occurs independently from scientific inquires such as our investigation: there is no self-selection of cases by researchers. German health insurance companies randomly conduct internal validation of claims data by cross-checking coded information with the original patient files. We also conducted a validation study by comparing data from the DAK-G database and the AAA registry hosted by the German Vascular Society. 17 We found that mortality, hospital length of stay, and use of EVAR had good internal validity for DAK-G data. Additional advantages of DAK-G data compared with AAA registry data include the availability of postdischarge follow-up data and the lack of reporting bias due to self-selection of submitted cases by physicians. Another limitation is that there is a significant risk selection for the compared approaches. It must be highlighted that this study aimed to investigate real-world data, which cannot replace RCTs. However, it could examine whether results from RCTs are similar to realworld experiences. Considering this limitation, the inversion of survival benefit after 1.5 years for iAAA repair could be interpreted as being caused by better durability of OAR and fewer reinterventions, with the caveat that confounding is still possible if younger and fitter patients undergo OAR. Unfortunately, health insurance claims data do not provide valid information regarding aneurysmrelated death or reinterventions for endoleaks. This limitation therefore needs to be taken into account when these results are interpreted.
Effect of time is important to consider when our data are compared with RCTs. None of the multicenter trials collected data beyond 2008, whereas our study covers from 2008 to 2015. It is possible that technical device improvement and training of the centers has an effect on outcomes. 7 Importantly, our study includes all ages and we have no exclusions. The main published studies of long-term outcomes use U.S. Medicare beneficiary data or the NIS, which are mostly limited to patients aged >65 years and in-hospital outcomes, respectively. About 800 invasive procedures in this study (>15% of cohort) were done for patients who were aged <65 years, which makes our study applicable to younger patients.
There are additional policy implications for the evidence found in our study. Major efforts are underway to implement an AAA ultrasound screening program in Germany to detect small aneurysms in the elderly. Hence, the rates of rAAA might continue to decline in the German population, and surgeons might operate on smaller AAAs where the benefits of EVAR and OAR are still uncertain and need to be continually researched. Comparative long-term results and cost-effectiveness of both approaches remain controversial, and international collaborations, such as the ICVR, can help create a learning network and could help to overcome limitations related to single-country investigations.
CONCLUSIONS
We found that in-hospital outcomes favor EVAR in Germany, which is comparable to findings reported in the U.S. and the UK. Trends toward lower long-term survival after discharge after EVAR are important and require future research and reflection by the vascular surgical community and continuous research. These findings, along with the expansion of EVAR use for both iAAA and rAAA, have major policy implications in light of AAA screening implementation in Germany, which is likely to detect smaller aneurysms in lower-risk groups.
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